IGLH:全面重新评价历史血管性血友病诊断与全血血小板聚集和功能的关系

2018-05-30 MedSci MedSci原创

对血管性血友病(VWD)的诊断,特别是对于1型仍具有一定的挑战性。目前的诊断指南强调同时出血症状和血管性血友病因子(VWF)水平<30‐40 IU/dL。历史诊断需要进行重新评估。我们通过标准化出血评分(BS)和中心实验室分析评估了综合护理中心过去VWD诊断的准确性,重点研究了全血VWF依赖的血小板功能。 我们的研究包括83名成人,被断中位数为20年前。我们通过多平台血小板聚集评估了B

血管性血友病(VWD)诊断,特别是对于1型仍具有一定的挑战性。目前的诊断指南强调同时出血症状和血管性血友病因子(VWF)水平<3040 IU/dL。历史诊断需要进行重新评估。我们通过标准化出血评分(BS)和中心实验室分析评估了综合护理中心过去VWD诊断的准确性,重点研究了全血VWF依赖的血小板功能。

我们的研究包括83名成人,被断中位数为20年前。我们通过多平台血小板聚集评估了BSVWF抗原和活动(最少3测量)FVIII,PFA-100®。并对32N2B和不清楚的病例进行了基因检测。

所有13/13(100%)类型329/32(90%)2型,以及10/38(26%)1(总体52/83(63%))患者符合VWD的当前标准。除了2 b亚型以外,所有确诊病例,BSPFA-100®异常,并RIPA减少或者缺缺失。所有的研究对象VWFFVIIIRIPAPFABS相关。38例患者中有10例有VWF(3550 IU/dL)较低,且VWF依赖的血小板功能可变。共有21/83例患者(25%)VWF:RCo (>50 IU/dL)重复测量正常。

血管性血友病与VWF依赖的全血血小板功能相关联,这些功能与传统的VWF测量相匹配。我们在25%的历史诊断患者中检测到正常的VWF,主要是1型患者,这意味着有必要对历史VWD的诊断进行系统的评估。

原始出处:

V. NummiR. Lassila, et. al.Comprehensive reevaluation of historical von Willebrand disease diagnosis in association with whole blood platelet aggregation and function

本文系梅斯医学MedSci原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1812347, encodeId=bb60181234e91, content=<a href='/topic/show?id=9ff9896405e' target=_blank style='color:#2F92EE;'>#血管性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89640, encryptionId=9ff9896405e, topicName=血管性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 16 20:43:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444378, encodeId=33eb14443e86e, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526233, encodeId=b989152623300, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600739, encodeId=e6371600e3952, content=<a href='/topic/show?id=6ea2890503c' target=_blank style='color:#2F92EE;'>#血小板聚集#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89050, encryptionId=6ea2890503c, topicName=血小板聚集)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590618798479, createdName=syscxl, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1812347, encodeId=bb60181234e91, content=<a href='/topic/show?id=9ff9896405e' target=_blank style='color:#2F92EE;'>#血管性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89640, encryptionId=9ff9896405e, topicName=血管性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 16 20:43:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444378, encodeId=33eb14443e86e, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526233, encodeId=b989152623300, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600739, encodeId=e6371600e3952, content=<a href='/topic/show?id=6ea2890503c' target=_blank style='color:#2F92EE;'>#血小板聚集#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89050, encryptionId=6ea2890503c, topicName=血小板聚集)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590618798479, createdName=syscxl, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2018-06-01 huagfeg
  3. [GetPortalCommentsPageByObjectIdResponse(id=1812347, encodeId=bb60181234e91, content=<a href='/topic/show?id=9ff9896405e' target=_blank style='color:#2F92EE;'>#血管性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89640, encryptionId=9ff9896405e, topicName=血管性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 16 20:43:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444378, encodeId=33eb14443e86e, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526233, encodeId=b989152623300, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600739, encodeId=e6371600e3952, content=<a href='/topic/show?id=6ea2890503c' target=_blank style='color:#2F92EE;'>#血小板聚集#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89050, encryptionId=6ea2890503c, topicName=血小板聚集)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590618798479, createdName=syscxl, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=)]
    2018-06-01 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1812347, encodeId=bb60181234e91, content=<a href='/topic/show?id=9ff9896405e' target=_blank style='color:#2F92EE;'>#血管性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89640, encryptionId=9ff9896405e, topicName=血管性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 16 20:43:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444378, encodeId=33eb14443e86e, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526233, encodeId=b989152623300, content=<a href='/topic/show?id=84d03692056' target=_blank style='color:#2F92EE;'>#历史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36920, encryptionId=84d03692056, topicName=历史)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=131011702315, createdName=cathymary, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600739, encodeId=e6371600e3952, content=<a href='/topic/show?id=6ea2890503c' target=_blank style='color:#2F92EE;'>#血小板聚集#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89050, encryptionId=6ea2890503c, topicName=血小板聚集)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590618798479, createdName=syscxl, createdTime=Fri Jun 01 10:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=)]

相关资讯

北大医院刘梅林等报告全国多中心研究:老年人50 mg阿司匹林也可有效抑制血小板聚集,且安全性好

较多老年人需要服用阿司匹林防治心脑血管病,但又担心出血风险。如何平衡老年人心血管获益以及出血风险,合理使用阿司匹林是临床应充分考虑的问题。

JAHA:基线血清纤维蛋白原升高对PCI后2年心血管严重不良事件的影响

基线纤维蛋白原水平升高与经皮冠脉介入治疗后的2年MACE相关。